Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Acceptability study of a new paediatric formulation of Orphacol® (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-?5-C27- steroid oxidoreductase deficiency or ?4-3-Oxosteroid-5ß-reductase deficiency. - ORPH-PAED-01
100 Clinical Results associated with Laboratoires C.T.R.S. SAS
0 Patents (Medical) associated with Laboratoires C.T.R.S. SAS
01 Apr 2014·médecine/sciencesQ4 · MEDICINE
L’observatoire économique du médicament orphelin : mythe ou réalité ?
Q4 · MEDICINE
Article
Author: Ferry, Antoine ; Duguet, Christophe
100 Deals associated with Laboratoires C.T.R.S. SAS
100 Translational Medicine associated with Laboratoires C.T.R.S. SAS